U.S. clinical-stage immunotherapeutics company Altimmune Inc. has completed with $14 million in its previously announced registered direct offering of common units and pre-funded units.

Altimmune intends to use the money raised to advance its continued advancement and development activities for its product pipeline.

The company will further use the funds for strategic growth opportunities including potential acquisitions and licensing transactions, and general working capital purposes.

U.S.-based investment banking firm Roth Capital Partners acted as sole placement agent for the offering.